Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection

Appendix A: Pediatric Antiretroviral Drug Information

Overview

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors (NRTIs)

Abacavir

Emtricitabine

Lamivudine

Tenofovir alafenamide

Tenofovir disoproxil fumarate

Zidovudine

Non-Nucleoside Analogue Reverse Transcriptase Inhibitors (NNRTIs)

Doravirine

Efavirenz

Etravirine

Nevirapine

Rilpivirine

Protease Inhibitors (PIs)

Atazanavir

Darunavir

Lopinavir/Ritonavir

Entry and Fusion Inhibitors

Fostemsavir

Ibalizumab

Maraviroc

Capsid Inhibitors 

Lenacapavir 

Integrase Inhibitors (INSTIs)

Bictegravir

Cabotegravir 

Dolutegravir

Elvitegravir

Raltegravir

Pharmacokinetic Enhancers

Cobicistat

Ritonavir

Fixed-Dose Combinations

Appendix A, Table 1. Antiretrovirals Available in Fixed-Dose Combination Tablets or as a Co-packaged Formulation, by Drug Class

Appendix A, Table 2. Antiretroviral Fixed-Dose Combination Tablets: Minimum Body Weights and Considerations for Use in Children and Adolescents

Archived Drugs

Didanosine

Enfuvirtide

Fosamprenavir

Indinavir

Nelfinavir

Saquinavir

Stavudine

Tipranavir